Grifols   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Barcelona Spain (1940)

Organization Overview

First Clinical Trial
1999
NCT00606905
First Marketed Drug
2017
sodium chloride
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Biomat USA, Inc | Biomat USA, Inc. | Biomat USA, Inc. (Sponsor) | Grifols Biologicals Inc. | Grifols Biologicals, LLC | Grifols Diagnostics Solutions, Inc | Grifols Japan K.K. | Grifols Shared Services North America | Grifols Therapeutics | Grifols Therapeutics Inc. | Grifols Therapeutics LLC | Instituto Grifols, S.A. | LABORATORIOS GRIFOLS | omitja@flsida.org, +3493 4978339

Active Ingredients

Marketed Drugs (1)

sodium chloride (2017)

Drugs in Phase 4 Trials (10)

Key: Grifols (5) Acquired (5)

albumin (Human) (Plasbumin) (17 trials)

antihemophilic factor viii human (Hemofil M) (6 trials)

antihemophilic factor viii (Recombinant) (Adynovate) (1 trial)

bivigam (2 trials)

emicizumab (Hemlibra) (1 trial)

immune globulin (human) (40 trials)

tetanus-diphtheria toxoid (2 trials)

tetanus immunoglobulin (1 trial)

von Willebrand factor (Wilate) (3 trials)

von Willebrand factor (recombinant) (Vonvendi) (3 trials)

Drugs in Phase 3 Trials (15)

Key: Grifols (11) Acquired (4)

albutein (2 trials)

alpha-1 antitrypsin (Prolastin) (16 trials)

antithrombin iii (human) (thrombate iii) (7 trials)

blood plasma (2 trials)

ciprofloxacin (cipro) (2 trials)

covid 19 immune globulin (1 trial)

fibrinogen (human) (RiaSTAP) (5 trials)

glucose monohydrate (1 trial)

hepatitis b immune globulin (human) (BayHep B) (5 trials)

human fibrin (4 trials)

naltrexone (revia) (1 trial)

sodium chloride (5 trials)

thrombin (human coagulation factor iia) (Evithrom) (2 trials)

thrombin (human coagulation factor iia) (Recombinant) (Recothrom) (1 trial)

zutectra (1 trial)

Drugs in Phase 2 Trials (19)

Key: Grifols (6) Acquired (13)

abvac40 (2 trials)

aflibercept (zaltrap) (1 trial)

akst4290 (4 trials)

alk4290 (2 trials)

alteplase (Activase) (1 trial)

bt063 (1 trial)

coagulation factor ix (Recombinant) (Rixubis) (1 trial)

COVID-19 convalescent plasma (2 trials)

fibrinolysin, human (3 trials)

grf6019 (2 trials)

grf6021 (2 trials)

hepatitis c immune globulin (1 trial)

IgM Concentrate (trimodulin) (1 trial)

indatuximab ravtansine (3 trials)

mometasone (elocon) (1 trial)

pentaglobin (1 trial)

thrombin (bovine) (Thrombostat) (1 trial)

tregalizumab (3 trials)

urokinase (kinlytic) (1 trial)

Drugs in Phase 1 Trials (3)

Key: Grifols (1) Acquired (2)

giga-2050 (1 trial)

igm enriched immunoglobulins (1 trial)

rabies immune globulin (human) (Kedrab) (1 trial)

Drugs in Other Trials (4)

Key: Grifols (0) Acquired (4)

azathioprine (imuran) (1 trial)

cyclosporine (sandimmune) (1 trial)

mycophenolate (myfortic) (1 trial)

tacrolimus (prograf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Acute Kidney Injury (Phase 4)

Acute-On-Chronic Liver Failure (Phase 3)

Afibrinogenemia (Phase 3)

Agammaglobulinemia (Phase 3)

alpha 1-Antitrypsin Deficiency (Phase 3)

Alzheimer Disease (Phase 3)

Amyloidosis (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Antithrombin III Deficiency (Phase 3)

Arterial Occlusive Diseases (Phase 2)

Ascites (Phase 4)

Brain Diseases (Phase 2)

Bronchiectasis (Phase 3)

Common Variable Immunodeficiency (Phase 3)

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Crohn Disease (Phase 3)

Cystic Fibrosis (Phase 2)

Deficiency Diseases (Phase 4)

Diabetes Complications (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetic Neuropathies (Phase 2)

Diphtheria (Phase 1)

Emphysema (Phase 3)

End Stage Liver Disease (Phase 3)

Epilepsy (Phase 3)

Fibrosis (Phase 4)

Hemophilia A (Phase 4)

Hemophilia B (Phase 2)

Hemorrhage (Phase 3)

Hepatic Encephalopathy (Phase 2)

Hepatic Insufficiency (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 3)

HIV Infections (Phase 3)

Hypotension (Phase 4)

IgG Deficiency (Phase 2)

Immunologic Deficiency Syndromes (Phase 4)

Infections (Phase 2)

Ischemia (Phase 2)

Liver Cirrhosis (Phase 4)

Liver Failure (Phase 3)

Lung Diseases, Obstructive (Phase 2)

Lupus Erythematosus, Cutaneous (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Macular Degeneration (Phase 2)

Motor Neuron Disease (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Muscle Weakness (Phase 4)

Muscular Diseases (Phase 2)

Myasthenia Gravis (Phase 4)

Peripheral Nervous System Diseases (Phase 2)

Poliomyelitis (Phase 3)

Polyneuropathies (Phase 3)

Polyradiculoneuropathy (Phase 3)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 3)

Postpoliomyelitis Syndrome (Phase 3)

Postural Orthostatic Tachycardia Syndrome (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Pulmonary Emphysema (Phase 3)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Rabies (Phase 1)

Recurrence (Phase 4)

Sclerosis (Phase 2)

Severe Combined Immunodeficiency (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Stiff-Person Syndrome (Phase 3)

Stroke (Phase 2)

Syndrome (Phase 3)

Tachycardia (Phase 2)

Tetanus (Phase 4)

Tetany (Phase 4)

Thrombosis (Phase 2)

Venous Thrombosis (Phase 1)

von Willebrand Diseases (Phase 4)

Wiskott-Aldrich Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 137
  • # of Trial APIs: 51